These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 15562128)

  • 41. Invasive meningococcal disease epidemiology and control measures: a framework for evaluation.
    Caro JJ; Möller J; Getsios D; Coudeville L; El-Hadi W; Chevat C; Nguyen VH; Caro I
    BMC Public Health; 2007 Jun; 7():130. PubMed ID: 17603880
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evaluation of the impact of serogroup C meningococcal disease vaccination program in Brazil and its regions: a population-based study, 2001-2013.
    Moraes C; Moraes JC; Silva GD; Duarte EC
    Mem Inst Oswaldo Cruz; 2017 Apr; 112(4):237-246. PubMed ID: 28327788
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Dramatic decline of serogroup C meningococcal disease in Catalonia (Spain) after a mass vaccination campaign with meningococcal C conjugated vaccine.
    Salleras L; Domínguez A; Cardeñosa N
    Vaccine; 2003 Jan; 21(7-8):729-33. PubMed ID: 12531350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vaccine strategies of meningococcal disease: results of a 10-year population-based study.
    Biebl A; Hartmann G; Bernhard C; Bechter E; Luckner-Hornischer A; Frühwirth M; Heuberger S; Offner F; Barbieri V; Simma B
    Eur J Pediatr; 2005 Dec; 164(12):735-40. PubMed ID: 16133244
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The decline of the incidence of meningococcal disease in Barcelona between 1988 and 2015: the influence of the vaccine against serogroup C.
    Manzanares-Laya S; Parés-Badell O; Gorrindo P; Simón P; Ros M; de Andrés A; López Segura N; Brió Sanagustín S; Vilella A; Rodrigo Gonzalo de Liria C; Orcau À; Caylà JA
    Med Clin (Barc); 2018 Nov; 151(10):390-396. PubMed ID: 29503027
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current Epidemiology and Trends in Meningococcal Disease-United States, 1996-2015.
    MacNeil JR; Blain AE; Wang X; Cohn AC
    Clin Infect Dis; 2018 Apr; 66(8):1276-1281. PubMed ID: 29126310
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Vaccination campaign following an increase in incidence of serogroup C meningococcal diseases in the department of Puy-de-Dôme (France).
    Lévy-Bruhl D; Perrocheau A; Mora M; Taha MK; Dromell-Chabrier S; Beytout J; Quatresous I
    Euro Surveill; 2002 May; 7(5):74-6. PubMed ID: 12631934
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure.
    Wang X; Shutt KA; Vuong JT; Cohn A; MacNeil J; Schmink S; Plikaytis B; Messonnier NE; Harrison LH; Clark TA; Mayer LW
    J Infect Dis; 2015 Jun; 211(12):1887-94. PubMed ID: 25556253
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy.
    Pace D
    Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
    de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
    Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Meningococcal disease before and after the introduction of meningococcal serogroup C conjugate vaccine. Federal District, Brazil.
    Tauil Mde C; Carvalho CS; Vieira AC; Waldman EA
    Braz J Infect Dis; 2014; 18(4):379-86. PubMed ID: 24698710
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Meningococcal disease and vaccination in North America.
    Pollard AJ; Scheifele D
    J Paediatr Child Health; 2001 Oct; 37(5):S20-7. PubMed ID: 11885732
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
    Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
    Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effectiveness of a single dose of the quadrivalent meningococcal conjugate vaccine, MenACWY-CRM, in the Korean Armed Forces.
    Im JH; Woo H; Ha BM; Lee JS; Chung MH; Jung J
    Vaccine; 2020 Jan; 38(4):730-732. PubMed ID: 31787413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epidemiology of invasive meningococcal disease in the Netherlands, 1960-2012: an analysis of national surveillance data.
    Bijlsma MW; Bekker V; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
    Lancet Infect Dis; 2014 Sep; 14(9):805-12. PubMed ID: 25104306
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seroprevalence of antibodies against serogroup C meningococci in the region of Valencia, Spain: Impact of meningococcal C conjugate vaccination.
    Pérez-Breva L; Abad-Torreblanca R; Martínez-Beneito MÁ; Puig-Barberà J; Alemán-Sánchez S; Morant-Talamante N; Sastre-Cantón M; Vázquez-Moreno JA; Díez-Domingo J
    Vaccine; 2017 May; 35(22):2949-2954. PubMed ID: 28438407
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epidemiological pattern of meningococcal disease in Valencia, Spain. Impact of a mass immunization campaign with meningococcal C polysaccharide vaccine.
    Pereiró I; Díez-Domingo J; Morant A; Gimeno C; Lerma M; San-Martín M; González A;
    Scand J Infect Dis; 2001; 33(8):581-4. PubMed ID: 11525350
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada.
    De Serres G; Billard MN; Gariépy MC; Rouleau I; Toth E; Landry M; Boulianne N; Gagné H; Gilca V; Deceuninck G; Ouakki M; Skowronski DM
    Vaccine; 2018 Dec; 36(52):8039-8046. PubMed ID: 30467063
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys.
    Mbaeyi S; Sampo E; Dinanibè K; Yaméogo I; Congo-Ouédraogo M; Tamboura M; Sawadogo G; Ouattara K; Sanou M; Kiemtoré T; Dioma G; Sanon B; Somlaré H; Kyetega A; Ba AK; Aké F; Tarbangdo F; Aboua FA; Donnou Y; Kamaté I; Patel JC; Schmink S; Spiller MW; Topaz N; Novak R; Wang X; Bicaba B; Sangaré L; Ouédraogo-Traoré R; Kristiansen PA
    Lancet Infect Dis; 2020 Dec; 20(12):1418-1425. PubMed ID: 32653071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.